ADXN — Addex Therapeutics Balance Sheet
0.000.00%
- CH₣6.67m
- CH₣4.41m
- CH₣0.41m
- 14
- 20
- 43
- 12
Annual balance sheet for Addex Therapeutics, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 18.7 | 20.5 | 6.96 | 3.87 | 3.34 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.068 | 0.324 | 0.598 | 0.151 | 0.016 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19.5 | 21.9 | 7.83 | 4.23 | 3.54 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.633 | 0.542 | 0.399 | 0.353 | 0.043 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 20.2 | 22.5 | 8.28 | 4.64 | 10.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.62 | 4.13 | 3.28 | 2.89 | 0.802 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 5.57 | 5.61 | 3.37 | 3.5 | 1 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 14.6 | 16.9 | 4.91 | 1.15 | 9.68 |
| Total Liabilities & Shareholders' Equity | 20.2 | 22.5 | 8.28 | 4.64 | 10.7 |
| Total Common Shares Outstanding |